Table 1.

Main characteristics at diagnosis and therapy at frontline, all patients (n = 400)

	Overall (n = 400)	No change in therapy based on MRD (n = 333)	Change in therapy based on MRD (n = 67)
Male (%)	55	57	45
Mean age, years (sd)	58.9 (0.4)	59.2 (0.7)	57.1 (1.3)
Myeloma type, (%)
IgG	55	56	46
IgA	19	19	20
Light chain only	19	17	27
High risk cytogenetics*, (%)	17	17	16
ISS, (%)
I	38	35	40
II	26	28	38
III	35	33	27
Hemoglobin, (g/dL) (sd)	12.5 (0.7)	12.6 (0.7)	12.1 (1.2)
High LDH levels, (%)	20	20	21
Induction treatment, (%)
CyBorD	19	19	19
VRD/VTD	45	49	40
Others	36	32	41
ASCT, yes (%)	78	78	81
Maintenance, yes (%)	82	82	91

CyBorD: bortezomib, cyclophosphamide, dexamethasone; VRD: bortezomib, lenalidomide, dexamethasone; VTD: bortezomib, thalidomide, dexamethasone; ASCT: Autologous Stem Cell Transplantation. When we compared both groups, we did not find any statistical significance, p > 0.05 in all comparisons

^*High-risk cytogenetics was defined as del 17p; t(4;14), t(14;16) or t(14;20). When we compared both groups, we did not find any statistical significance, p > 0.05 in all comparisons